Paper Details

  1. Home
  2. Paper Details

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.

Author: DoiToshihiko, JohneAndreas, MatsubaraNobuaki, NaitoTateaki, SarholzBarbara, ShitaraKohei, TsushimaTakahiro, WatanabeMorihiro, YamazakiKentaro

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

A Phase I clinical trial in Japanese patients with solid tumors determined the recommended Phase II dose of tepotinib, a selective MET inhibitor, to be 500 mg once daily. This dose was based on safety and tolerability data obtained in the trial.
Paper Details　
Original Abstract of the Article :
Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has been defined, based on the first-in-man trial conducted in the USA and Europe. We carried out a mul...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401714/

データ提供：米国国立医学図書館（NLM）

Tepotinib: A Potential Oasis in the Desert of MET-Driven Cancers

MET inhibition is a promising strategy for treating cancers driven by mesenchymal-epithelial transition factor (MET) overexpression. This Phase I trial evaluates the safety and efficacy of tepotinib, a novel oral MET inhibitor, in Japanese patients with solid tumors. The researchers aim to establish the recommended Phase II dose of tepotinib, paving the way for further clinical investigations into its potential as a cancer treatment.

Tepotinib: A Potential Breakthrough in MET-Inhibition

The Phase I trial found that tepotinib was generally well-tolerated, with a recommended Phase II dose of 500 mg once daily. This finding sets the stage for further clinical trials to explore tepotinib's efficacy in specific MET-driven cancers, potentially offering new hope for patients with these challenging conditions.

Navigating the Complexities of Cancer Treatment

The study underscores the importance of carefully evaluating new cancer treatments, ensuring their safety and efficacy before widespread clinical application. The findings pave the way for further research into tepotinib's potential as a valuable therapeutic option for patients with MET-driven cancers.

Dr. Camel's Conclusion

This Phase I trial is like a camel caravan exploring a new oasis in the desert of MET-driven cancers. The study demonstrates the potential of tepotinib as a well-tolerated and promising MET inhibitor, offering hope for patients with these challenging conditions. Further research is crucial to fully understand tepotinib's efficacy in specific MET-driven cancers.

Date :
  1. Date Completed 2020-09-17
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

32328660

DOI: Digital Object Identifier

PMC7401714

Related Literature

Article Analysis
・Effects of tepotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.